Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08QGR
|
|||
| Drug Name |
PMID26560530-Compound-34
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
National Cancer Center (S. Korea)
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H6N2S3
|
|||
| Canonical SMILES |
CC1=C(SSC1=S)C2=NC=CN=C2
|
|||
| InChI |
1S/C8H6N2S3/c1-5-7(12-13-8(5)11)6-4-9-2-3-10-6/h2-4H,1H3
|
|||
| InChIKey |
CKNAQFVBEHDJQV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 64224-21-1
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:77319
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.